Vmbook Online ordering

Rosetta Genomics Ltd

Rosetta Genomics Ltd. is a molecular diagnostics company focused on the development and commercialization of a full range of molecular tests based on its proprietary platform for detecting and translating the complex language of miRNas, a new class of genetic regulators. The company's miRview tests are designed to provide physicians with actionable information to diagnose and treat various pathologies, including cancer, and have been clinically validated through multiple studies.

As of the most recent data, the company has not been consistently profitable and has accumulated significant net losses in the past. According to the company's financial statements, for the year ended December 31, 2019, Rosetta Genomics reported a net loss of $6.3 million, compared to a net loss of $5.7 million for the year ended December 31, 2018. The company's revenue for the year ended December 31, 2019, was $2.4 million, compared to $2.5 million for the year ended December 31, 2018.

It is important to note that the company has filed for Chapter 11 bankruptcy in the United States in August 2020, and is in the process of reorganization. The company's common stock was delisted from the NASDAQ stock exchange on September 14, 2020.

As a result, it is recommended to exercise caution when considering an investment in the company, and to thoroughly research the company's current financial status, bankruptcy proceedings, and plans for reorganization before making any investment decisions.

The company's growth prospects are hard to determine due to the bankruptcy, but it's worth mentioning that the miRNA-based diagnostics market is expected to grow in the next years, driven by the increasing incidence of cancer and other diseases, growing demand for personalized medicine, and technological advancements.